1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Differences in Legal Positioning of Package Inserts between Japan, US, Europe Highlighted
July 11, 2011
- Rivastigmine “Highly Effective”in Early Treatment of AD: Prof. Nakamura
July 11, 2011
- Pfizer Aims to Boost Sales of Long-listed Drugs by Adding Indications, Dosage Forms
July 11, 2011
- MAA Accepted by EMA for Perampanel: Eisai
July 11, 2011
- Rivastigmine Is Recommended for Mild AD: Dr Endo of NCGG
July 11, 2011
- Nippon Kayaku: Pharm Sales Up 1.3% to ¥50,339 Mil.
July 11, 2011
- Protect NHI Prices of Essential Drugs: Mr Matsumori of Pfizer Japan
July 11, 2011
- More Participation in Homecare Essential to Increase Demand for Pharmacists: Report
July 11, 2011
- Maruishi Expects Growth in Domestic Sales in FY2011
July 11, 2011
- Applications Based on Data from Public Domain Recommended for 8 Drugs
July 11, 2011
- NST Reduces Hospitalization Cost by ¥0.4 Mil per Patient: NCGM
July 11, 2011
- KHK Preparing for Expected Leap in Growth from 2014-2015: President Matsuda
July 11, 2011
- Korosho Abolishes Confirmation Application System for Regenerative Medicines
July 11, 2011
- MRs should Help Improve Quality of Healthcare as Medical Team Members: Prof. Muto
July 11, 2011
- Astellas Sells DPP-4 Inhibitor-related Patent Estate to Royalty Pharma for US$609 Mil.
July 11, 2011
- FDA Accepts Pfizer's Application for Axitinib for RCC
July 11, 2011
- Celecoxib Significantly Lowers Incidence of Ulcers vs Loxoprofen
July 11, 2011
- CMIC to Acquire Investigational Drug Manufacturing Facilities from Daiichi Sankyo
July 11, 2011
- Regenerative Medicine Industry Organization Kicks Off
July 11, 2011
- JES Calls for Approval of Monotherapy with Novel Antiepileptic Agents
July 11, 2011
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…